IOPIDINE 1% is indicated to control or prevent post surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery. (Clinical trials have been conducted in trabeculoplasty, iridotomy and capsulotomy).
IOPIDINE 5mg/ml is indicated for short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery. The IOP lowering efficacy of IOPIDINE diminishes over time in most patients. Although some patients have received successful treatment with IOPIDINE for longer periods, the benefit for most patients is less than one month. The addition of IOPIDINE to patients already using two aqueous suppressing drugs (i.e. beta-blockers plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because IOPIDINE is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP.
VisionCare Ophthalmic Technologies, Inc. a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), announced...
Aerie Pharmaceuticals announced the submission of its New Drug Application (NDA) to the FDA for Rhopressa (netarsudil ophthalmic solution) 0.02%....
Aerie Pharmaceuticals, Inc. announced that, in their review of Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, the members of...
Santen Pharmaceutical Co., Ltd. announced that it has obtained manufacturing and marketing approval for the dry eye treatment Diquas LX Ophthalmic Solution 3% (diquafosol sodium) in Japan.